Cipla Limited — Investor Meet, 27-01-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Cipla's Q3 FY26 revenue was Rs 7,074 Cr, flat YoY, with PAT at Rs 676 Cr. EBITDA margin stood at 17.7%, primarily affected by lower generic Revlimid sales and a Rs 276 Cr exceptional charge from a new labor code. FY26 EBITDA margin guidance is now ~21%. India's business delivered robust 10% YoY growth, led by chronic therapies. North America revenue was $167 million, with Lanreotide production paused due to a partner's FDA observations; resupply is expected H1 FY27. A strong US pipeline includes four respiratory launches (like generic Advair, Victoza) and three peptide assets. Management is confident new launches will offset Revlimid's impact.